Clinical trials
Phase 1 Overweight trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
124 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 17 |
| 2025 | 25 |
| 2026 | 26 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 80 |
| Recruiting | 21 |
| Active, not recruiting | 12 |
| Terminated | 4 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 24 |
| Novo Nordisk A/S | 22 |
| Pfizer | 10 |
| Amgen | 9 |
| Altimmune, Inc. | 3 |
| AstraZeneca | 3 |
| Columbia University | 3 |
| Kailera | 3 |
| California Polytechnic State University-San Luis Obispo | 2 |
| Carmot Therapeutics, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Overweight | 124 |
| Obesity | 113 |
| Diabetes Mellitus, Type 2 | 12 |
| Diabetes Mellitus | 9 |
| Non-alcoholic Fatty Liver Disease | 7 |
| Weight Loss | 6 |
| Body Weight | 4 |
| Insulin Resistance | 4 |
| Diabetes Mellitus, Type 1 | 3 |
| Fatty Liver | 3 |
Trials
Showing 1 to 25 of 124. Each trial links to its page on Pharma Observatory.
24 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.